The FASEB Journal express article 10.1096/fj.04-2183fje. Published online October 20, 2004. ©2004 FASEB

Diabetic nephropathy is the leading cause of end‐stage renal disease, for which effective therapy to prevent the progression at advanced stages remains to be established. There is also a long debate whether diabetic glomerular injury is reversible or not. Lipoatrophic diabetes, a syndrome caused by paucity of adipose tissue, is characterized by severe insulin resistance, dyslipidemia, and fatty liver. Here, we show that a genetic model of lipoatrophic diabetes (A‐ZIP/F‐1 mice) manifests a typical renal injury observed in human diabetic nephropathy that is associated with glomerular hypertrophy, diffuse and pronounced mesangial widening, accumulation of extracellular matrix proteins, podocyte damage, and overt proteinuria. By crossing A‐ZIP/F‐1 mice with transgenic mice overexpressing an adipocyte‐derived hormone leptin, we also reveal that leptin completely prevents the development of hyperglycemia and nephropathy in A‐ZIP/F‐1 mice. Furthermore, continuous leptin administration to A‐ZIP/F‐1 mice by minipump beginning at 40 weeks of age significantly alleviates the glomerular injury and proteinuria. These findings demonstrate the therapeutic usefulness of leptin at least for a certain type of diabetic nephropathy. The model presented here will serve as a novel tool to analyze the molecular mechanism underlying not only the progression but also the regression of diabetic nephropathy.

[1]  B. Wajchenberg,et al.  The natural history of diabetic nephropathy in type I diabetes and the role of metabolic control in its prevention, reversibility and clinical course , 2007, Acta diabetologia latina.

[2]  L. Szczech,et al.  Leptin and Renal Disease , 2006, Seminars in dialysis.

[3]  K. Nakao,et al.  Role of Prostaglandin E Receptor EP1 Subtype in the Development of Renal Injury in Genetically Hypertensive Rats , 2003, Hypertension.

[4]  K. Nakao,et al.  Leptin as an adjunct of insulin therapy in insulin-deficient diabetes , 2003, Diabetologia.

[5]  H. Kawachi,et al.  Expression of Podocyte-Associated Molecules in Acquired Human Kidney Diseases 2 , 2009 .

[6]  F. Anania,et al.  Leptin induces increased α2(I) collagen gene expression in cultured rat hepatic stellate cells , 2003, Journal of cellular biochemistry.

[7]  K. Nakao,et al.  Angiogenic protein Cyr61 is expressed by podocytes in anti-Thy-1 glomerulonephritis. , 2003, Journal of the American Society of Nephrology : JASN.

[8]  G. Camussi,et al.  Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. , 2003, Diabetes.

[9]  S. Hong,et al.  Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. , 2003, Biochemical and biophysical research communications.

[10]  T. Oite,et al.  Up-regulation of connexin43 in glomerular podocytes in response to injury. , 2002, The American journal of pathology.

[11]  Y. Takei,et al.  Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. , 2002, Gastroenterology.

[12]  M. Mukoyama,et al.  Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. , 2001, Journal of the American Society of Nephrology : JASN.

[13]  M. Reitman,et al.  Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. , 2001, Diabetes.

[14]  M. Mukoyama,et al.  Altered growth response to prostaglandin E2 and its receptor signaling in mesangial cells from stroke-prone spontaneously hypertensive rats , 2001, Journal of hypertension.

[15]  K. Sharma,et al.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Salant,et al.  Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. , 2000, Kidney international.

[17]  K. Hosoda,et al.  Pathophysiological role of leptin in obesity-related hypertension. , 2000, The Journal of clinical investigation.

[18]  M. Laville,et al.  Normal reproductive function in leptin-deficient patients with lipoatropic diabetes. , 2000, Journal of Clinical Endocrinology and Metabolism.

[19]  R. G. Nelson,et al.  Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria , 1999, Diabetologia.

[20]  F. Thaiss,et al.  Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells: Potential role in glomerulosclerosis1 , 1999 .

[21]  K. Hosoda,et al.  Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. , 1999, Diabetes.

[22]  G. Inoue,et al.  Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes. , 1999, Diabetes.

[23]  G. Wolf,et al.  Molecular mechanisms of diabetic renal hypertrophy. , 1999, Kidney international.

[24]  M. Olive,et al.  Life without white fat: a transgenic mouse. , 1998, Genes & development.

[25]  D. Sutherland,et al.  Reversal of lesions of diabetic nephropathy after pancreas transplantation. , 1998, The New England journal of medicine.

[26]  D. Cooper,et al.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.

[27]  L Peltonen,et al.  Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. , 1998, Molecular cell.

[28]  R. Zeller,et al.  Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. , 1997, Experimental cell research.

[29]  S. O’Rahilly,et al.  Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.

[30]  T. Meyer,et al.  Podocyte loss and progressive glomerular injury in type II diabetes. , 1997, The Journal of clinical investigation.

[31]  S. Thorgeirsson,et al.  Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[32]  Jia Guo,et al.  Neutralization of TGF-β by Anti-TGF-β Antibody Attenuates Kidney Hypertrophy and the Enhanced Extracellular Matrix Gene Expression in STZ-Induced Diabetic Mice , 1996, Diabetes.

[33]  E. Ritz,et al.  Diabetic nephropathy in type II diabetes. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  N. Tamura,et al.  Molecular cloning of rat obese cDNA and augmented gene expression in genetically obese Zucker fatty (fa/fa) rats. , 1995, The Journal of clinical investigation.

[35]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[36]  E Ruoslahti,et al.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Orloff,et al.  Reversal of Mesangial Enlargement in Rats With Long-standing Diabetes by Whole Pancreas Transplantation , 1986, Diabetes.

[38]  S. A. Kumar,et al.  REVERSAL OF DIABETIC NEPHROPATHY IN HUMAN CADAVERIC KIDNEYS AFTER TRANSPLANTATION INTO NON-DIABETIC RECIPIENTS , 1983, The Lancet.